<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01654640</url>
  </required_header>
  <id_info>
    <org_study_id>DW_Metformin</org_study_id>
    <nct_id>NCT01654640</nct_id>
  </id_info>
  <brief_title>The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine</brief_title>
  <official_title>Phase 4 Study of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the evaluation of effect of metformin on obesity and metabolic
      disturbance in patients taking clozapine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators are going to examine the effect of metformin on obesity and
      metabolic disturbance in patients with schizophrenia who have taken clozapine.The metformin
      500mg will be administrated per oral twice a day for 24 weeks and for control group, placebo
      will be given same route and process.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of weight</measure>
    <time_frame>baseline, 12 weeks, 24 weeks</time_frame>
    <description>change of weight after 12-week, 24-week. calculation; (weight of 12-week - weight of baseline)/baseline weight (weight of 24-week - weight of baseline)/baseline weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Symptom Scale(PANSS)</measure>
    <time_frame>baseline, 12 weeks, 24 weeks</time_frame>
    <description>baseline, 1-week, 4-week, 12-week, 24-week(end-point)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MADRS(montgomery asberg depression rating scale)</measure>
    <time_frame>baseline, 12 weeks, 24 weeks</time_frame>
    <description>baseline, 1-week, 4-week, 12-week, 24-week(end-point)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-severity(CGI-S)</measure>
    <time_frame>baseline, 6 weeks, 24 weeks</time_frame>
    <description>baseline, 1-week, 4-week, 12-week, 24-week(end-point)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-improvement(CGI-I)</measure>
    <time_frame>baseline, 12 weeks, 24 weeks</time_frame>
    <description>baseline, 1-week, 4-week, 12-week, 24-week(end-point)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck's Depression Inventory(BDI)</measure>
    <time_frame>baseline, 12 weeks, 24 weeks</time_frame>
    <description>baseline, 1-week, 4-week, 12-week, 24-week(end-point)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liverpool University Neuroleptic Side Effect Rating Scale(LUNSERS)</measure>
    <time_frame>baseline, 12 weeks, 24 weeks</time_frame>
    <description>baseline, 1-week, 4-week, 12-week, 24-week(end-point)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organization Quality of Life-BREF (WHOQOL-BREF)</measure>
    <time_frame>baseline, 12 weeks, 24 weeks</time_frame>
    <description>baseline, 1-week, 4-week, 12-week, 24-week(end-point)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short form(36) Health survey (SF-36)</measure>
    <time_frame>baseline, 12 weeks, 24 weeks</time_frame>
    <description>baseline, 1-week, 4-week, 12-week, 24-week(end-point)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abdominal fat amount CT</measure>
    <time_frame>baseline, 12 weeks, 24 weeks</time_frame>
    <description>baseline, 12-week, 24-week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of prevalence of metabolic syndrome</measure>
    <time_frame>baseline, 12 weeks, 24 weeks</time_frame>
    <description>waist circumference, blood pressure cholesterol,triglyceride, HDL-cholesterol,fasting glucose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Metformin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 500mg 1 tablet p.o. bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet p.o. bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>metformin 500mg p.o. bid for 24 weeks</description>
    <arm_group_label>Metformin group</arm_group_label>
    <other_name>Diabex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for metformin)</intervention_name>
    <description>placebo 1T bid</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 ~ 65

          -  Patient with schizophrenia according to DSM-IV criteria

          -  Patient have signed on the informed consent, and well understood the objective and
             procedure of this study.

          -  Patient taking clozapine 3months or more

          -  Patient increased in weight more than 10 % of that of before antipsychotics use

        Exclusion Criteria:

          -  Patient taking other antipsychotics with clozapine

          -  Patient in treatment of diabetes

          -  Patient in treatment of dyslipidemia

          -  Allergy or hypersensitivity to metformin

          -  Pregnant or breast-feeding female patient.

          -  Patient with severe medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Min Ahn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Jeong Lee, MD</last_name>
    <email>hjlee.np@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyun Jeong Lee, MD</last_name>
      <email>hjlee.np@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yong Min Ahn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyun Jeong Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yong Min Ahn, MD., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.snuh.org/</url>
    <description>study site</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2012</study_first_posted>
  <last_update_submitted>December 7, 2015</last_update_submitted>
  <last_update_submitted_qc>December 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yong Min Ahn</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>obesity</keyword>
  <keyword>clozapine</keyword>
  <keyword>metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

